A股異動丨華北製藥連續兩日漲停 全球17年來首款阿爾茲海默症新藥獲批
格隆匯11月5日丨華北製藥(600812.SH)連續兩日漲停,報7.81元,成交8.72億元,總市值127.4億元。11月2日,國家藥品監督管理局批准了上海綠谷製藥有限公司治療阿爾茨海默病新藥——九期一(甘露特鈉,代號:GV-971)的上市申請。該藥的獲批上市,填補了過去17年AD治療領域無新藥上市的空白,為廣大飽受阿爾茨海默病困擾的患者帶來“福音”。華北製藥是中國最大的化學制藥企業之一,此前曾公告用於治療老年痴呆症的中藥新藥參烏膠囊已完成三期臨牀。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.